Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 19, 2022

Nivolumab Plus Chemotherapy vs Placebo Plus Chemotherapy in HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or GEJ Junction Cancer

The Lancet Oncology


Additional Info

The Lancet Oncology
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Lancet Oncol 2022 Jan 11;[EPub Ahead of Print], YK Kang, LT Chen, MH Ryu, DY Oh, SC Oh, HC Chung, KW Lee, T Omori, K Shitara, S Sakuramoto, IJ Chung, K Yamaguchi, K Kato, SJ Sym, S Kadowaki, K Tsuji, JS Chen, LY Bai, SY Oh, Y Choda, H Yasui, K Takeuchi, Y Hirashima, S Hagihara, N Boku

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading